Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective-Reference-Cited by-同舟云学术

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

Published:2024-04 Issue: Volume:70 Page:102536
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Gougis Paul,Jochum Floriane^ORCID,Abbar Baptiste^ORCID,Dumas Elise,Bihan Kevin,Lebrun-Vignes Bénédicte,Moslehi Javid,Spano Jean-Philippe,Laas Enora,Hotton Judicael,Reyal Fabien,Hamy Anne-Sophie,Salem Joe-Elie^ORCID

Publisher

Elsevier BV

Reference33 articles.

1. Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance;Geraud;Annu Rev Pharmacol Toxicol,2021

2. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

3. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients;Journal of Neurology;2024-09-03

2. Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review;Clinical Journal of Gastroenterology;2024-08-20

3. Genetic factors in the pathogenesis of cardio-oncology;Journal of Translational Medicine;2024-08-05

4. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation;Cancers;2024-07-12

5. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart;Nature Reviews Cancer;2024-07-09